HHS Public Access

Author manuscript
J Pediatr. Author manuscript; available in PMC 2021 March 23.
Author Manuscript

Published in final edited form as:

J Pediatr. 2020 February ; 217: 66–72.e1. doi:10.1016/j.jpeds.2019.07.074.

The Effect of Extended Continuous Positive Airway Pressure on

Changes in Lung Volumes in Stable Premature Infants: A
Randomized Controlled Trial
Ryan Lam, MD1, Diane Schilling, RRT1, Brian Scottoline, MD, PhD1, Astrid Platteau, MD1,
Meike Niederhausen, PhD2, Kelli C. Lund, MD1, Robert L. Schelonka, MD1, Kelvin D.
MacDonald, MD, RRT3, Cindy T. McEvoy, MD, MCR1
Author Manuscript

1Division of Neonatology, Department of Pediatrics, Oregon Health & Science University,

Portland, OR
2Biostatistics
and Design Program, Oregon Health & Science University–Portland State University
School of Public Health, Portland, OR
3Division of Pediatric Pulmonology, Oregon Health & Science University, Portland, OR

Abstract
Objective—To compare changes in lung volumes, as measured by functional residual capacity
(FRC), through to discharge in stable infants randomized to 2 weeks of extended continuous
positive airway pressure CPAP (eCPAP) vs CPAP discontinuation (dCPAP).
Author Manuscript

Study design—Infants born at ≤32 weeks of gestation requiring ≥24 hours of CPAP were
randomized to 2 weeks of eCPAP vs dCPAP when meeting CPAP stability criteria. FRC was
measured with the nitrogen washout technique. Infants were stratified by gestational age (<28 and
≥ 28 weeks) and twin gestation. A linear mixed-effects model was used to evaluate the change in
FRC between the 2 groups. Data were analyzed blinded to treatment group allocation.

Results—Fifty infants were randomized with 6 excluded, for a total of 44 infants. Baseline
characteristics were similar in the 2 groups. The infants randomized to eCPAP vs dCPAP had a
greater increase in FRC from randomization through 2 weeks (12.6 mL vs 6.4 mL; adjusted 95%
CI, 0.78–13.47; P = .03) and from randomization through discharge (27.2 mL vs 17.1 mL;
adjusted 95% CI, 2.61–17.59; P = .01).

Conclusions—Premature infants randomized to eCPAP had a significantly greater increase in

Author Manuscript

FRC through discharge compared with those randomized to dCPAP. An increased change in FRC
may lead to improved respiratory health.

Trial registration—ClinicalTrials.gov: NCT02249143.

Nasal continuous positive airway pressure (CPAP) is the standard of care for the initial
support of premature infants with respiratory distress syndrome to establish and maintain

Reprint requests: Cindy T. McEvoy, MD, MCR, Department of Pediatrics, Oregon Health & Science University, 707 SW Gaines Road
(CDRC-P), Portland, OR 97239. mcevoyc@ohsu.edu.
Data Statement
Data sharing statement available at www.jpeds.com.
 Lam et al. Page 2

their functional residual capacity (FRC) while minimizing potential volutrauma from
mechanical ventilation.1–3 Infants who require intubation are usually extubated to CPAP to
Author Manuscript

maintain alveolar recruitment and prevent atelectasis. A meta-analysis demonstrated that

premature infants randomized to CPAP vs intubation at delivery have decreased
bronchopulmonary dysplasia at 36 weeks of postmenstrual age (PMA).4 In addition to acute
physiological benefits, studies in animal models have shown an improvement in lung growth
after CPAP,5 as well as decreased inflammatory cytokines,6 decreased airway reactivity,6
and increased angiogenic growth factors.7 The beneficial effects of CPAP in preterm infants
may stem from avoidance of mechanical ventilation and promotion of lung growth through
mechanical stretch.

Although early application of CPAP after delivery is currently standard management, there
is no consensus as to when or how to wean stable premature infants off CPAP.8 Prolonged
CPAP also has potential adverse side effects, including nasal breakdown, delayed oral feeds,
Author Manuscript

prolonged hospitalization, decreased parental bonding, and developmental therapies.8 In

addition, parents often urge neonatal intensive care unit (NICU) providers to discontinue
CPAP as soon as possible to keep the infant’s face un-obstructed or to facilitate oral feeding.
Trials to evaluate CPAP weaning have done so when specific CPAP respiratory stability
criteria were met.9,10 The primary aim of the present study was to quantify and compare
changes in lung volumes (as measured by FRC) in stable, convalescing preterm infants
receiving CPAP and randomized to an additional 2 weeks of CPAP (extended CPAP
[eCPAP]) vs CPAP discontinuation (dCPAP; usual care). We hypothesized that compared
with infants randomized to dCPAP, infants randomized to eCPAP would demonstrate a
greater increase in FRC at end of the 2-week study period and at hospital discharge.

Secondary aims of the study were to determine whether eCPAP was associated with
Author Manuscript

improvements in other pulmonary function test (PFT) measures, including FRC normalized
per kg of body weight, passive respiratory compliance (Crs), Crs normalized per kg, passive
respiratory resistance, and tidal volumes. The PMA at which the infants achieved full nipple
feeds and were discharged to home was also assessed.

Methods
This study was conducted in the level IV NICU at Oregon Health & Science University
(OHSU). The protocol was approved by the OHSU Institutional Review Board, and
informed consent was obtained for all enrolled patients. The study was registered at
ClinicalTrials.gov (NCT02249143), and recruitment occurred from September 2014 through
May 2016. No changes to the protocol or outcome measures were made after trial
registration. Infants who were born at ≤32 weeks of gestation, treated with CPAP for ≥24
Author Manuscript

hours for respiratory distress (as initial treatment or following extubation), and met
predesignated CPAP stability criteria were eligible for inclusion. Exclusion criteria included
significant congenital heart disease, major congenital malformations, chromosomal
abnormalities, culture-proven sepsis at consent, complex maternal conditions, clinical
instability, and greater than twin gestation.

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 3

In the OHSU NICU, all CPAP is administered as bubble CPAP through appropriately sized
Hudson nasal prongs11 (Teleflex, Morrisville, North Carolina) with an 8 Fr orogastric tube
Author Manuscript

to vent the stomach. The nares are assessed every 4 hours for redness or inadvertent
pressure, and the prongs are repositioned as needed. The OHSU NICU follows established
clinical consensus guidelines for CPAP discontinuation. In these guidelines, preterm infants
are maintained on CPAP until CPAP stability criteria9 are met for a minimum of 12 hours,
after which CPAP is discontinued and the infant is placed on room air. The published CPAP
stability criteria9 are CPAP of 4–5 cm H2O, no oxygen requirement, respiratory rate <70
breaths/minute, retraction score of ≤1, <3 self-resolving apneic episodes (<20 seconds)
and/or bradycardia (<100 bpm) and/or desaturations (pulse oximeter oxygen saturation,
SpO2 <86%) per hour for the last 6 hours, average SpO2 >86% for at least 90% of the time
over the past 24 hours, not being treated for PDA or sepsis, and tolerating time off CPAP
during routine care (up to 15 minutes).
Author Manuscript

The clinical team determined the patient’s respiratory management. When an infant met the
CPAP stability criteria, study consent was obtained, baseline noninvasive PFTs without
sedation were performed, and the infant was randomized to eCPAP or dCPAP. PFTs were
also performed at the end of the 2-week treatment period and before discharge, at 35–36
weeks PMA. A standard operating protocol with specific acceptance criteria was followed
for the PFTs, and a single, highly trained respiratory therapist performed all the tests. One
investigator masked to treatment allocation reviewed all tests for quality.

Permuted block randomization with opaque sealed envelopes was used to stratify the infants
by gestational age at delivery (<28 vs ≥28 weeks) and twins. The envelopes were prepared
by a statistician not involved in the study to optimize the masking of randomization. After
the randomization PFT, the envelope was opened and the patient placed on the allocated
Author Manuscript

therapy. All infants were monitored daily for adverse events. If both twins were recruited
into the study, the second twin was placed in the same treatment group as the first
randomized twin.12

Infants randomized to the dCPAP group failed the room air trial if they exhibited at least 2 of
the following9: respiratory rate >80 breaths/minute for >12 hours, increased apnea and/or
bradycardia and/or desaturations (>2 episodes requiring moderate to vigorous stimulation
per hour for the previous 6-hour period), any oxygen requirement to maintain SpO2 >86%, a
blood gas pH of <7.2, PaCO2 >65 mm Hg, and a major apnea or bradycardia event requiring
resuscitation. An infant who failed dCPAP resumed CPAP at the previous level, and dCPAP
was reattempted within the next 7 days. If this second attempt again was unsuccessful, the
infant was dropped from the study. Infants randomized to eCPAP were taken off CPAP for
Author Manuscript

up to 7 days if abdominal distention with feeding intolerance or nasal septal breakdown

occurred. If symptoms resolved within 7 days, eCPAP was reattempted. The infant was
dropped from the study if signs of CPAP intolerance reoccurred a second time.

PFTs were measured with an infant pulmonary function cart (SensorMedics 2600;
SensorMedics, Yorba Linda, California) at the infant’s bedside in the NICU. All testing was
done with the infant supine and quiet at least 30 minutes following a feeding. The

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 4

measurements were done with the infant breathing through a face mask connected to a 3-
way valve.13
Author Manuscript

For the nitrogen washout technique, calibration was done with 2 known volumes, and a
calibration line was constructed at the specific flow rate and used to correlate the nitrogen
washed out to the infant’s FRC. The system corrected for dead space and corrected the FRC
to body temperature, pressure, and water-saturated conditions. Acceptance criteria included
infant supine and quietly asleep, test initiated at end expiration, no leak on washout tracing,
consistent tracings, and ≥3 measurements with a coefficient of variation <10%.13,14

Tidal volume was calculated by digital integration of the flow signal.13,15 For the single-
breath occlusion technique, the airway was briefly occluded at end inspiration until an
airway pressure plateau was observed and the Hering–Breuer reflex was invoked. The linear
portion of the passive flow–volume curve was identified, a regression line was drawn to
Author Manuscript

obtain the best fit, and respiratory system compliance and resistance were calculated.
Acceptance criteria as outlined by the American Thoracic Society/European Respiratory
Society were followed.15,16

Statistical Analyses
The primary outcome was the change in FRC from randomization through discharge in the 2
groups of infants. We hypothesized that a 15% improvement in FRC would be demonstrated
at the end of the 2 weeks of treatment and at discharge in stable infants randomized to
eCPAP vs dCPAP. Based on our previous studies,13 with an α value of 0.05 and a power of
0.80, sample size calculation determined the need for a minimum of 22 subjects in each
group. We chose a 15% difference as meaningful, because changes in PFTs of this
magnitude are used by the National Heart, Lung, and Blood Institute to define a positive
Author Manuscript

response to bronchodilators.17

All outcomes were analyzed by a statistician blinded to the infants’ treatment assignments.
Maternal and infant characteristics were compared using the independent-samples t-test for
continuous measures (or the Wilcoxon-Mann-Whitney test for nonnormal distributions) and
the χ2 test for categorical variables. FRC values over time were modeled using linear mixed-
effects regression with treatment group-time interaction and repeated measures for the
randomization, 2 week, and discharge time points. Compound symmetric covariance
structures were used to account for the correlation of FRC values within each patient. We
compared outcomes between the 2 groups and included adjustments for sex, twin gestation,
and weight at randomization. Sensitivity analyses randomly removing 1 of each pair of twins
were done to determine the effect of including both twins on the difference in FRC between
Author Manuscript

the 2 treatment groups. Group differences in the secondary outcomes were tested at
randomization, 2 weeks, and discharge using the independent-samples t-test. Analyses were
run in R version 3.3.1 (R Project for Statistical Computing, Vienna, Austria)18 using the
nlme package lme function19 for the mixed-effects modeling.

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 5

Results
Author Manuscript

We screened a total of 116 patients born at ≤32 weeks of gestation for eligibility, and 50
patients met the inclusion and exclusion criteria and were randomized. Twenty-four infants
were assigned to eCPAP, and 26 were assigned to dCPAP (Figure 1; available at
www.jpeds.com). Six infants were excluded because they failed CPAP discontinuation, their
parents withdrew consent, or their PFTs were technically unacceptable. The serial PFTs of
the remaining 44 infants (22 per group) were analyzed for the primary outcome. Six infants
(3 in each group) were transported back to their referring hospital at the end of the 2-week
treatment period, and their discharge values were recorded as missing.

The maternal and infant characteristics of the randomized infants who completed the PFTs
are shown in Table I. There were no significant between-group differences in demographic
characteristics, although the infants randomized to eCPAP tended to be more mature and
Author Manuscript

thus to have a higher birth weight and tended to have more twins. The lowest gestational age
in each group was 25.3 weeks. There were comparable numbers of patients born at <28
weeks of gestation in the 2 groups.

Both groups of patients were randomized at a mean of ~32 weeks PMA, and there was no
between-group difference in weight or FRC at the time of randomization (Table II). The
infants randomized to eCPAP had a significantly greater increase in FRC from
randomization through 2 weeks of treatment (12.6 mL vs 6.4 mL; adjusted mean difference,
7.13; 95% CI, 0.78–13.47; P = .03) and from randomization through discharge (27.2 mL vs
17.1 mL; adjusted difference, 10.10; 95% CI, 2.61–17.59; P = .01) (Table II and Figure 2).
At discharge, the FRC was 68.1 mL (28.4 mL/kg) in the eCPAP group vs 57.1 mL (25.4
mL/kg) in the dCPAP group (adjusted difference, 6.62; 95% CI, 0.02–13.22; P = .049). Both
Author Manuscript

groups of infants were discharged at comparable PMAs and had comparable weights at the
PFTs performed just before discharge (Table II). Oral feeds were initiated in both groups
according to feeding cues, and patients achieved full feeds at comparable PMAs, 35.8 weeks
in the eCPAP group and 36.0 weeks in the dCPAP group.

Secondary PFT outcomes are shown in Table III (available at www.jpeds.com). FRC/kg was
significantly different between the groups at the end of 2 weeks of treatment and at
discharge. There was no difference in passive respiratory compliance (Crs) or in Crs/kg at
baseline or any of the subsequent time points. The respiratory resistance was comparable in
the 2 groups at baseline, significantly lower in the eCPAP group at 2 weeks, but comparable
in the 2 groups again at discharge. The infants randomized to eCPAP had a statistically
lower tidal volume at randomization, but these measurements were comparable at the end of
the 2-week treatment period and at discharge.
Author Manuscript

The infants randomized to eCPAP tolerated it well with no significant adverse events,
including no events of nasal breakdown or feeding intolerance. One patient in the dCPAP
arm failed the trial off CPAP twice and was dropped from the study. The parents of 1 patient
in the eCPAP group withdrew consent.

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 6

Safety Monitoring
Author Manuscript

No significant adverse events were attributed to the study.

Discussion
This single-center, randomized pilot trial demonstrated that eCPAP administered to
convalescing preterm infants who were born at ≤32 weeks of gestation, meeting predefined
stability criteria for CPAP discontinuation, had a significantly greater increase in FRC from
randomization through the 2-week treatment period and, importantly, also through
discharge.

Despite advances in neonatal care, prematurity still results in impaired lung development20
with decreased airway21 and parenchymal function22 and increased respiratory morbidity
into adulthood. Currently, there are no known therapies to stimulate lung growth and
Author Manuscript

decrease respiratory morbidity after preterm birth. Our present results suggest that in stable
preterm infants, eCPAP may be a nonpharmacologic and safe therapeutic strategy to
stimulate lung growth. Infants follow along a pulmonary function percentile established
shortly after birth,23,24 so a greater increase in FRC at NICU discharge could translate into
longer-term respiratory benefits over the infant’s lifetime.

We are aware of no randomized trials defining the optimal PMA to discontinue CPAP in
stable preterm infants. Early CPAP may benefit the preterm lung by minimizing injury, but
clinical and animal data indicate that the mechanical stretch of the lung with CPAP may
stimulate lung growth. Congenital diaphragmatic hernia prevents in utero lung expansion
and results in hypoplastic lungs,25,26 and complete congenital airway obstruction prevents
lung fluid from leaving the trachea and produces a large, hyperplastic lung.27 Animal
Author Manuscript

models of in utero congenital diaphragmatic hernia have shown that fetal trachea occlusion
increases the lungs’ distending pressure and results in increased fetal lung growth,28,29
capillary growth, and epithelial branching.30–33

The mechanical strain from CPAP applied to the lungs of young animals can stimulate lung
growth and have other beneficial molecular effects. Tracheostomized ferrets exposed to 6
cmH2O CPAP vs atmospheric pressure for 2 weeks demonstrated a 40% increase in total
lung capacity with unchanged pressure volume curves indicating accelerated lung growth vs
simple lung distention.5 High levels vs low levels of CPAP in ferrets significantly increased
lung volume and airway size by volumetric computed tomography scan.6 In addition, cyclic
stretch of cultured airway epithelial cells increases the release of nitric oxide and placental
growth factor,7 which are important determinants of angiogenesis. In animal models,
inhibition of angiogenic factors inhibits alveolarization, and replacement restores
Author Manuscript

alveolarization. These studies support a physiological basis for eCPAP-related lung growth
in the premature lung.

A strength of our study was the consistent management of all preterm infants on bubble
CPAP, with randomization occurring when conservative CPAP stability criteria were met.9
This was adhered to by all of the neonatologists and health care providers at our NICU.
Worldwide, there is wide variation in when and how premature infants are weaned off CPAP,

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 7

even within the same NICU.34,35 Many neonatologists will attempt to wean patients off
Author Manuscript

CPAP as quickly as possible. In contrast, the longstanding practice at Columbia University

Medical Center, where early CPAP was championed, is to continue infants on CPAP until
34.5 weeks PMA.36 Some approaches to weaning premature infants off CPAP include
weaning the CPAP pressure with variable frequency to low levels before discontinuation,
time cycling between on and off CPAP for variable durations, and transitioning from CPAP
to high-flow to low-flow nasal cannula and then to room air. All of our patients met the
predefined stability criteria at approximately 32 weeks of age, and only 1 of the 26 (3.8%)
assigned to the dCPAP group failed these criteria, necessitating reapplication of CPAP. Many
centers wean patients from CPAP to high-flow nasal cannula, but this was not evaluated in
our study.

Another strength of the study is the application of reproducible PFTs to document changes
in lung volumes. We powered the study to show a 15% increase in FRC in the eCPAP group
Author Manuscript

vs the dCPAP group and demonstrated a significant increase of >15%. To provide

perspective, one of the most effective therapies to decrease morbidity in preterm infants is a
single course of antenatal corticosteroids, which has been shown to increase FRC and Crs by
approximately 50% in preterm animals and humans.37 We have previously reported that
neonatal PFT measurements of FRC and Crs correlate with clinical outcomes; a 10%–12%
improvement in Crs measured soon after birth correlated with a significant decrease in
wheeze through 12 months of age in offspring of pregnant smokers randomized to vitamin C
vs placebo during pregnancy.15

CPAP has a number of acute and potentially long-term beneficial effects for the preterm
lung, but it also has potential side effects, including nasal breakdown and gastric distention.8
Although our sample size was small for these outcomes, there was no increase in adverse
Author Manuscript

events and no differences in time to full oral feeds, weight, and PMA at discharge between
the 2 groups.

Although this was a randomized trial, we acknowledge several limitations. This was a pilot,
single-center trial with a relatively small sample size; however, the desired sample size was
achieved to address the hypothesis with the application of reproducible PFTs. Four of the 50
randomized infants were excluded from the overall PFT analysis, and even though this is a
small number, it may have biased the outcome. It was not ethical or feasible to blind the
study to investigators or parents, but PFTs were reviewed and statistical analyses were
performed blinded to treatment. In addition, standard American Thoracic Society/European
Respiratory Society criteria were applied to the acceptance of the PFT testing. The median
gestational age of the randomized infants was 29.6 weeks (IQR, 27.5–30.8 weeks), so these
Author Manuscript

results might not apply to more immature infants. We also did not perform follow-up PFTs
after discharge to continue to follow the PFT trajectories.

There are several potential explanations for the significantly greater increase in FRC in the
infants randomized to eCPAP vs those randomized to dCPAP. Similar to animal studies of
CPAP application,5 there was no significant difference in the Crs between the 2 randomized
groups, even though the FRC was larger in the eCPAP group. These measurements support
increased lung growth vs lung overdistension with eCPAP. Passive respiratory resistance was

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 8

not different in the 2 groups, although the measurement technique used in this study
Author Manuscript

primarily measures resistance in the large airways. Measurements of forced expiratory

flows, considered a more sensitive measure of the peripheral airways,38 were not performed.
Although the eCPAP infants may have larger lungs, the present study did not assess whether
there was improved gas exchange. Some published evidence suggests that CPAP may also
stimulate angiogenesis, which could translate into improved lung diffusion capacity39;
however, lung diffusion capacity was not measured in this study, because this technique is
not currently available for infants in the NICU.

In conclusion, stable convalescing preterm infants born at ≤32 weeks of gestation and
randomized to eCPAP have a significantly greater increase in FRC at the end of the 2-week
treatment and through discharge compared with infants randomized to dCPAP. Premature
infants have altered lung development with impaired alveolarization and an increased risk of
subsequent respiratory disease. eCPAP in stable preterm infants may be a novel, safe, and
Author Manuscript

nonpharmacologic therapeutic strategy to stimulate lung growth, alter pulmonary function

trajectories, and improve childhood respiratory outcomes.

Acknowledgments
Supported in part by NHLBI HL105447, NHLBI HL129060, and NIH UH3OD023288 (to C.M. and K.M.) and
Friends of the Doernbecher Foundation and Oregon Clinical and Translational Research Institute (UL1TR000128)
from the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH). The
content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
The authors declare no conflicts of interest.

We thank the parents, physicians, nurses, neonatal nurse practitioners, and respiratory therapists in the NICU for
their support of this study and Dr Manuel Durand for a careful manuscript review.

Glossary
Author Manuscript

CPAP Continuous positive airway pressure

Crs Passive respiratory compliance

dCPAP Discontinued continuous positive airway pressure

eCPAP Extended continuous positive airway pressure

FRC Functional residual capacity

NICU Neonatal intensive care unit

OHSU Oregon Health & Science University

Author Manuscript

PFT Pulmonary function test

PMA Postmenstrual age

References
1. Dunn MS, Kaempf J, de Klerk A, de Klerk R, Reilly M, Howard D, et al. Randomized trial
comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics
2011;128:e1069–76. [PubMed: 22025591]

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 9

2. Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Early CPAP versus
surfactant in extremely preterm infants. N Engl J Med 2010;362:1970–9. [PubMed: 20472939]
Author Manuscript

3. Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB. Nasal CPAP or intubation at
birth for very preterm infants. N Engl J Med 2008;358:700–8. [PubMed: 18272893]
4. Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for
preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev
2016;6:CD001243.
5. Zhang S, Garbutt V, McBride JT. Strain-induced growth of the immature lung. J Appl Physiol
(1985) 1996;81:1471–6. [PubMed: 8904555]
6. Xue Z, Zhang L, Liu Y, Gunst SJ, Tepper RS. Chronic inflation of ferret lungs with CPAP reduces
airway smooth muscle contractility in vivo and in vitro. J Appl Physiol (1985) 2008;104:610–5.
[PubMed: 18096756]
7. Mohammed KA, Nasreen N, Tepper RS, Antony VB. Cyclic stretch induces PIGF expression in
bronchial airway epithelial cells via nitric oxide release. Am J Physiol Lung Cell Mol Physiol
2007;292:L559–66. [PubMed: 17028267]
8. Bamat N, Jensen EA, Kirpalani H. Duration of continuous positive airway pressure in premature
Author Manuscript

infants. Semin Fetal Neonatal Med 2016;21:189–95. [PubMed: 26948885]

9. Todd DA, Wright A, Broom M, Chauhan M, Meskell S, Cameron C, et al. Methods of weaning
preterm babies <30 weeks gestation off CPAP: a multicentre randomised controlled trial. Arch Dis
Child Fetal Neonatal Ed 2012;97:F236–40. [PubMed: 22611116]
10. Abdel-Hady H, Shouman B, Aly H. Early weaning from CPAP to high flow nasal cannula in
preterm infants is associated with prolonged oxygen requirement: a randomized controlled trial.
Early Hum Dev 2011;87: 205002D8.
11. De Paoli AG, Davis PG, Faber B, Morley CJ. Devices and pressure sources for administration of
nasal continuous positive airway pressure (NCPAP) in preterm neonates. Cochrane Database Syst
Rev 2008;1: CD002977.
12. Bernardo J, Nowacki A, Martin R, Fanaroff JM, Hibbs AM. Multiples and parents of multiples
prefer same arm randomization of siblings in neonatal trials. J Perinatol 2015;35:208–13.
[PubMed: 25341196]
13. McEvoy C, Venigalla S, Schilling D, Clay N, Spitale P, Nguyen T. Respiratory function in healthy
Author Manuscript

late preterm infants delivered at 33–36 weeks of gestation. J Pediatr 2013;162:464–9. [PubMed:
23140884]
14. Morris MG, Gustafsson P, Tepper R, Gappa M, Stocks J. The bias flow nitrogen washout technique
for measuring the functional residual capacity in infants. ERS/ATS Task Force on Standards for
Infant Respiratory Function Testing. Eur Respir J 2001;17:529–36. [PubMed: 11405534]
15. McEvoy CT, Schilling D, Clay N, Jackson K, Go MD, Spitale P, et al. Vitamin C supplementation
for pregnant smoking women and pulmonary function in their newborn infants: a randomized
clinical trial. JAMA 2014;311:2074–82. [PubMed: 24838476]
16. Gappa M, Colin AA, Goetz I, Stocks J. Passive respiratory mechanics: the occlusion techniques.
Eur Respir J 2001;17:141–8. [PubMed: 11307744]
17. National Asthma Education and Prevention Program. Expert panel report: Guidelines for the
diagnosis and management of asthmaupdate on selected topics—2002. J Allergy Clin Immunol
2002;110(5 suppl):S141–219. [PubMed: 12542074]
18. R Core Team. R: a language and environment for statistical computing. Available at: http://www.R-
project.org/. Accessed August 21, 2019.
Author Manuscript

19. Pinheiro J, Bates D, DebRoy S, Sarkar D. R Core Team 2019. nlme: Linear and nonlinear mixed
effects models. R package version 3.1–141 Available at: http://CRAN.R-project.org/
package=nlme. Accessed August 21, 2019.
20. McEvoy C, Schilling D, Peters D, Tillotson C, Spitale P, Wallen L, et al. Respiratory compliance in
preterm infants after a single rescue course of antenatal steroids: a randomized controlled trial. Am
J Obstet Gynecol 2010;202:544.e1–9. [PubMed: 20227053]
21. Friedrich L, Pitrez PM, Stein RT, Goldani M, Tepper R, Jones MH. Growth rate of lung function in
healthy preterm infants. Am J Respir Crit Care Med 2007;176:1269–73. [PubMed: 17885265]

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 10

22. Balinotti JE, Tiller CJ, Llapur CJ, Jones MH, Kimmel RN, Coates CE, et al. Growth of the lung
parenchyma early in life. Am J Respir Crit Care Med 2009;179:134–7. [PubMed: 18996997]
Author Manuscript

23. Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory health and
disease. Lancet Respir Med 2013;1:728–42. [PubMed: 24429276]
24. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy
and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet
2007;370:758–64. [PubMed: 17765525]
25. Langham MR Jr, Kays DW, Ledbetter DJ, Frentzen B, Sanford LL, Richards DS. Congenital
diaphragmatic hernia. Epidemiology and outcome. Clin Perinatol 1996;23:671–88. [PubMed:
8982563]
26. Harrison MR, Keller RL, Hawgood SB, Kitterman JA, Sandberg PL, Farmer DL, et al. A
randomized trial of fetal endoscopic tracheal occlusion for severe fetal congenital diaphragmatic
hernia. N Engl J Med 2003;349:1916–24. [PubMed: 14614166]
27. Scurry JP, Adamson TM, Cussen LJ. Fetal lung growth in laryngeal atresia and tracheal agenesis.
Aust Paediatr J 1989;25:47–51. [PubMed: 2730470]
28. Khan PA, Cloutier M, Piedboeuf B. Tracheal occlusion: a review of obstructing fetal lungs to make
Author Manuscript

them grow and mature. Am J Med Genet C Semin Med Genet 2007;145C:125–38. [PubMed:
17436297]
29. Flecknoe SJ, Crossley KJ, Zuccala GM, Searle JE, Allison BJ, Wallace MJ, et al. Increased lung
expansion alters lung growth but not alveolar epithelial cell differentiation in newborn lambs. Am
J Physiol Lung Cell Mol Physiol 2007;292:L454–61. [PubMed: 17028266]
30. Schmidt AF, Goncalves FL, Nassr AC, Pereira LA, Farmer D, Sbragia L. Antenatal steroid and
tracheal occlusion restore vascular endothelial growth factor receptors in congenital diaphragmatic
hernia rat model. Am J Obstet Gynecol 2010;203:184.e13–20.
31. Unbekandt M, del Moral PM, Sala FG, Bellusci S, Warburton D, Fleury V. Tracheal occlusion
increases the rate of epithelial branching of embryonic mouse lung via the FGF10-FGFR2b-
Sprouty2 pathway. Mech Dev 2008;125:314–24. [PubMed: 18082381]
32. Cloutier M, Maltais F, Piedboeuf B. Increased distension stimulates distal capillary growth as well
as expression of specific angiogenesis genes in fetal mouse lungs. Exp Lung Res 2008;34:101–13.
[PubMed: 18307120]
Author Manuscript

33. Mesas-Burgos C, Nord M, Didon L, Eklof AC, Frenckner B. Gene expression analysis after
prenatal tracheal ligation in fetal rat as a model of stimulated lung growth. J Pediatr Surg
2009;44:720–8. [PubMed: 19361631]
34. Bowe L, Clarke P. Current use of nasal continuous positive airways pressure in neonates. Arch Dis
Child Fetal Neonatal Ed 2005;90: F92–3.
35. Jardine L, Davies MW. Withdrawal of neonatal continuous positive airway pressure: current
practice in Australia. Pediatr Int 2008;50:572–5. [PubMed: 19143985]
36. Polin RA, Sahni R. Newer experience with CPAP. Semin Neonatol 2002;7:379–89. [PubMed:
12464500]
37. McEvoy C, Bowling S, Williamson K, Stewart M, Durand M. Functional residual capacity and
passive compliance measurements after antenatal steroid therapy in preterm infants. Pediatr
Pulmonol 2001;31:425–30. [PubMed: 11389574]
38. Jones M, Castile R, Davis S, Kisling J, Filbrun D, Flucke R, et al. Forced expiratory flows and
volumes in infants. Normative data and lung growth. Am J Respir Crit Care Med 2000;161(2 Pt
1):353–9. [PubMed: 10673171]
Author Manuscript

39. Assaf SJ, Chang DV, Tiller CJ, Kisling JA, Case J, Mund JA, et al. Lung parenchymal development
in premature infants without bronchopulmonary dysplasia. Pediatr Pulmonol 2015;50:1313–9.
[PubMed: 25462113]

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 11
Author Manuscript
Author Manuscript
Author Manuscript

Figure 1.
CONSORT diagram of randomized premature infants. Enrollment, randomization, and the
study of randomized infants through discharge.
Author Manuscript

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 12
Author Manuscript
Author Manuscript
Author Manuscript

Figure 2.
FRC in randomized patients. Changes in FRC (mean ± SEM) in the eCPAP group (red) and
the dCPAP group (blue) in 44 patients (22 in each group) at randomization, in 22 patients
with eCPAP and 21 patients with dCPAP at the 2-week time point, and in 17 patients with
eCPAP and 18 patients with dCPAP at discharge. The solid lines denote the treatment period
from randomization through the 2 weeks of treatment, and the dashed lines denote the
interval from the end of treatment to discharge. P = .03 for the change in FRC from
randomization to the end of 2 weeks of treatment between the randomized groups; P = .01
for the change in FRC from randomization to discharge between the randomized groups.
FRC values over time were modeled using linear mixed-effects regression models with
repeated measures for time, treatment–time interaction, and adjusting for sex, twins, and
Author Manuscript

weight at randomization.

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 13

Table I.

Maternal and infant characteristics

Author Manuscript

Characteristics eCPAP (N = 22) dCPAP (N = 22)

Maternal age, y, mean (SD) 29.7 (7.3) 31.2 (7.2)
Gravida, median (IQR) 1.5 (1,6) 2 (1,3.8)
Antenatal steroids, n (%) 19 (91) 17 (77)
Cesarean delivery, n (%) 11 (50) 16 (73)
Birth weight, g, mean (SD) 1405 (417) 1222 (389)
Gestational age, wk, mean (SD) 29.5 (1.9) 28.7 (2.2)
White race, n (%) 17 (77) 19 (86)
Male sex, n (%) 9 (41) 14 (64)
Twin gestation, n (%) 7 (32) 4 (18)
1-minute Apgar score, median (IQR) 6 (5.3–7.0) 4 (2.0–7.0)
Author Manuscript

5-minute Apgar score, median (IQR) 8 (6.0–8.8) 7 (6.0–8.0)

<28 weeks gestation, n (%) 8 (36) 9 (41)
Surfactant, n (%) 4 (18) 10 (46)

Days of mechanical ventilation, median (IQR)* 0 (0,0) 0 (0,1)

Days of CPAP before randomization into study, median (IQR) 12.0 (5.8–28.8) 16.5 (10.3–32.3)
Days of oxygen, median (IQR) 0 (0–2.8) 0 (0–4.5)

*
P < .05; P values are from the independent-samples t test for means, Wilcoxon–Mann–Whitney test for medians, and χ2 test for counts.
Author Manuscript
Author Manuscript

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Lam et al. Page 14

Table II.

Infant characteristics and FRC changes from randomization through discharge

Author Manuscript

Characteristics eCPAP (N = 22) dCPAP (N = 22) P value

PMA at randomization, wk 32.2 (0.73) 32.0 (0.80) .58
Weight at randomization, g 1567 (293) 1482 (323) .36

FRC at randomization, mL 40.5 (11.8) 41.5 (10.6) .15*

Average change in FRC, randomization to 2 wk, mL 12.6 (11.4) 6.4 (10.1) .03*

Average change in FRC, randomization to discharge, mL 27.2 (12.5) 17.1 (11.7) .01*
PMA at discharge PFT, wk 35.8 (0.63) 36.0 (1.02) .57
Weight at discharge PFT, g 2381 (228) 2271 (440) .35

FRC at discharge, mL 68.1 (9.2) 57.1 (12.0) .049*

Values are mean (SD); P values are from an independent-samples t test unless noted otherwise. FRC values are obtained in 44 patients (22 in each
Author Manuscript

group) at randomization, in 22 patients with eCPAP and 21 patients with dCPAP (1 technically unacceptable) at the 2-week time point, and in 17
patients with eCPAP (3 infants back-transported to the referring hospital and 2 with technically unacceptable PFT) and 18 patients with dCPAP at
discharge (3 infants back-transported to the referring hospital and 1 with technically unacceptable PFT). PMA and weight at discharge are based on
19 patients in each group.
*
Linear mixed-effects regression models with repeated measures for time, treatment vs time interaction, and adjusting for sex, twins, and weight at
randomization.
Author Manuscript
Author Manuscript

J Pediatr. Author manuscript; available in PMC 2021 March 23.

 Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Table III.

Secondary pulmonary function measurements in randomized patients

Measures eCPAP (N = 22) dCPAP (N = 22) P value

Lam et al.

FRC/kg at randomization, mL/kg 26.0 (5.5) 27.9 (4.6) .20

FRC/kg at 2 weeks of treatment, mL/kg* 28.1 (4.9) 25.2 (3.7) .03

† 28.4 (2.5) 25.4 (4.9) .03

FRC/kg at discharge, mL/kg
Crs at randomization, mL/cm H2O 2.20 (0.56) 1.93 (0.49) .10
Crs/kg at randomization, mL/cm H2O/kg 1.37 (0.28) 1.32 (0.28) .63
‡ 2.50 (0.54) 2.22 (0.36) .06
Crs at 2 weeks of treatment, mL/cm H2O

‡ 1.28 (0.28) 1.17 (0.18) .16

Crs/kg at 2 weeks of treatment, mL/cm H2O/kg

§ 2.57 (0.51) 2.48 (0.55) .61

Crs at discharge, mL/cm H2O

§ 1.08 (0.18) 1.12 (0.21) .55

Crs/kg at discharge, mL/cm H2O/kg

Rrs at randomization, cm H2O/mL/s 0.054 (0.014) 0.053 (0.009) .86

‡ 0.061 (0.014) 0.074 (0.021) .03
Rrs at 2 weeks of treatment, cm H2O/mL/s

§ 0.073 (0.019) 0.082 (0.022) .19

Rrs at discharge, cm H2O/mL/s

Vt at randomization, mL/kg 7.1 (1.01) 7.8 (0.97) .02

‡ 7.6 (1.06) 7.4 (0.90) .40
Vt at 2 weeks of treatment, mL/kg
§ 7.3 (1.04) 7.3 (0.64) .99
Vt at discharge, mL/kg

J Pediatr. Author manuscript; available in PMC 2021 March 23.

Rrs, passive respiratory resistance; Vt/kg, tidal volume per kilogram.

Values are mean (SD); P values are from an independent-samples t test unless noted otherwise.
*
Acceptable tests for FRC/kg in 22 patients with eCPAP and 21 patients with dCPAP.
†
Acceptable tests for FRC/kg in 17 patients with eCPAP and 18 patients with dCPAP.
‡
Acceptable tests obtained in 20 patients with eCPAP and 21 patients with dCPAP.
§
Acceptable tests obtained in 18 patients with eCPAP and 19 patients with dCPAP.
Page 15